

# Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BA231E021A3MEN.html>

Date: May 2018

Pages: 142

Price: US\$ 2,480.00 (Single User License)

ID: BA231E021A3MEN

## Abstracts

### Report Summary

Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Benign Prostatic Hyperplasia (BPH) Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Benign Prostatic Hyperplasia (BPH) Drugs worldwide, with company and product introduction, position in the Benign Prostatic Hyperplasia (BPH) Drugs market

Market status and development trend of Benign Prostatic Hyperplasia (BPH) Drugs by types and applications

Cost and profit status of Benign Prostatic Hyperplasia (BPH) Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market as:

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-blocker

Phosphodiesterase Type-5 Inhibitors

5-alpha-Reductase Inhibitors

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Clinics

Others

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Bayer HealthCare

Bristol-Myers Squibb

Valeant Pharmaceuticals

Endo Pharmaceuticals

Foresee Pharmaceuticals

Madrigal Pharmaceuticals

Merck

Novartis

Spectrum Pharmaceuticals

Takeda Pharmaceuticals

Teva

Advaxis

ANI Pharmaceuticals

BHR Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS**

- 1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs in This Report
- 1.2 Commercial Types of Benign Prostatic Hyperplasia (BPH) Drugs
  - 1.2.1 Alpha-blocker
  - 1.2.2 Phosphodiesterase Type-5 Inhibitors
  - 1.2.3 5-alpha-Reductase Inhibitors
- 1.3 Downstream Application of Benign Prostatic Hyperplasia (BPH) Drugs
  - 1.3.1 Hospitals
  - 1.3.2 Clinics
  - 1.3.3 Others
- 1.4 Development History of Benign Prostatic Hyperplasia (BPH) Drugs
- 1.5 Market Status and Trend of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2023
  - 1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017
- 2.2 Sales Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
  - 2.2.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
  - 2.2.2 Sales Value of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
- 2.3 Production Market of Benign Prostatic Hyperplasia (BPH) Drugs by Regions
- 2.4 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs 2018-2023
  - 2.4.1 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs 2018-2023
  - 2.4.2 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Types
- 3.2 Sales Value of Benign Prostatic Hyperplasia (BPH) Drugs by Types
- 3.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM**

## **INDUSTRY**

4.1 Global Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry

4.2 Global Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries

5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)

5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)

5.1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

5.1.4 Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

5.1.5 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

5.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers

5.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)

5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)

5.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)

5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries

6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)

6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)

- 6.1.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 6.1.4 UK Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 6.1.5 France Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 6.1.6 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 6.1.7 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 6.1.8 Spain Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 6.1.9 Benelux Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
- 6.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
  - 6.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
  - 6.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
- 6.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 7.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries
  - 7.1.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)
  - 7.1.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)
  - 7.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
  - 7.1.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
  - 7.1.5 India Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
  - 7.1.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
  - 7.1.7 Australia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)
- 7.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)
  - 7.3.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)
- 7.4 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status by

Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

8.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries

8.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)

8.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)

8.1.3 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

8.1.4 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

8.1.5 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

8.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers

8.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)

8.3.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)

8.3.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)

8.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Countries

9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2017)

9.1.3 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

9.1.4 Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status (2013-2017)

9.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Manufacturers



9.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2017)

9.3.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2017)

9.4 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS**

10.1 Global Economy Situation and Trend Overview

10.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 11 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

11.1 Production Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers

11.2 Production Value of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers

11.3 Basic Information of Benign Prostatic Hyperplasia (BPH) Drugs by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer

11.3.2 Employees and Revenue Level of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

## **CHAPTER 12 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

12.1 Astellas Pharma

12.1.1 Company profile



- 12.1.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
- 12.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
- 12.2 Eli Lilly
  - 12.2.1 Company profile
  - 12.2.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 12.3 GlaxoSmithKline
  - 12.3.1 Company profile
  - 12.3.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.3.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 12.4 Sanofi
  - 12.4.1 Company profile
  - 12.4.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 12.5 ADC Therapeutics
  - 12.5.1 Company profile
  - 12.5.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of ADC Therapeutics
- 12.6 Bayer HealthCare
  - 12.6.1 Company profile
  - 12.6.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
- 12.7 Bristol-Myers Squibb
  - 12.7.1 Company profile
  - 12.7.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.7.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 12.8 Valeant Pharmaceuticals
  - 12.8.1 Company profile
  - 12.8.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.8.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals
- 12.9 Endo Pharmaceuticals

- 12.9.1 Company profile
- 12.9.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
- 12.9.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
- 12.10 Foresee Pharmaceuticals
  - 12.10.1 Company profile
  - 12.10.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.10.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Foresee Pharmaceuticals
- 12.11 Madrigal Pharmaceuticals
  - 12.11.1 Company profile
  - 12.11.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.11.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Madrigal Pharmaceuticals
- 12.12 Merck
  - 12.12.1 Company profile
  - 12.12.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.12.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Merck
- 12.13 Novartis
  - 12.13.1 Company profile
  - 12.13.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.13.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 12.14 Spectrum Pharmaceuticals
  - 12.14.1 Company profile
  - 12.14.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.14.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Spectrum Pharmaceuticals
- 12.15 Takeda Pharmaceuticals
  - 12.15.1 Company profile
  - 12.15.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
  - 12.15.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
- 12.16 Teva
- 12.17 Advaxis
- 12.18 ANI Pharmaceuticals
- 12.19 BHR Pharma

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS**

- 13.1 Industry Chain of Benign Prostatic Hyperplasia (BPH) Drugs
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS**

- 14.1 Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 14.2 Raw Materials Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 14.3 Labor Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 14.4 Manufacturing Expenses Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

- 16.1 Methodology/Research Approach
  - 16.1.1 Research Programs/Design
  - 16.1.2 Market Size Estimation
  - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
  - 16.2.1 Secondary Sources
  - 16.2.2 Primary Sources
- 16.3 Reference

## I would like to order

Product name: Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BA231E021A3MEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BA231E021A3MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

